BioCentury
ARTICLE | Clinical News

Daratumumab: Preliminary Phase II data

February 9, 2015 8:00 AM UTC

Preliminary data from the 2-part, open-label, international Phase II Sirius MMY2002 trial in 124 MM patients showed that 16 mg/kg daratumumab led to an ORR of 29.2% and a median duration of response o...